A randomized phase i clinical trial of hydrovax-chikv, a novel inactivated chikungunya virus vaccine

Active Cooperative Agreement Awarded Last action

Award ID
U44AI152995
Recipient
Awarding agency
Obligated
$4,223,731

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 90% complete
Originally
Place of performance
Beaverton, OR 97006, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment $980,257
Amendment $980,963
Amendment $175
Amendment $985,958
Amendment $985,958
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Original award $290,420
Show all 11

Subawards

Subrecipient Amount Awarded
Subrecipient not on record Funds for R&D work $46,953
Duke University Funding for clinical trial services $145,596
Subrecipient not on record Funds for R&D work $46,953
Duke University To develop and conduct an up to 48 subject Phase I vaccine clinical trial to assess safety and immunogenicity of an inactivated chikungunya virus vaccine in… $432,095
Oregon Health & Science University Dr. Slifka's group will be responsible for measuring neutralizing antibody responses against CHIKV virus using PRNT50 and LNI-based approaches from… $46,953

Quick answers

Who received award U44AI152995?

U44AI152995 was awarded to Najit Technologies, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2020.

How much is award U44AI152995 worth?

$4,223,731 has been obligated on U44AI152995.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login